Drug Combination Details
| General Information of the Combination (ID: C10156) | |||||
|---|---|---|---|---|---|
| Name | Vincristine NP Info | + | Tolfenamic acid Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Brain cancer
[ICD-11: 2A00]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Down-regulation | Expression | BIRC5 | Molecule Info |
Pathway MAP
|
|
| Biological
Regulation |
Induction | Cell cycle arrest in G2/M phase | ||||
| In-vitro Model | Daoy | CVCL_1167 | Medulloblastoma | Homo sapiens | ||
| D283 Med | CVCL_1155 | Medulloblastoma | Homo sapiens | |||
| Experimental
Result(s) |
Combination of clotam and vincristine enhances anti-proliferative effect in medulloblastoma cells. | |||||
| References | ||||
|---|---|---|---|---|
| Reference 1 | Combination of clotam and vincristine enhances anti-proliferative effect in medulloblastoma cells. Gene. 2019 Jul 15;705:67-76. | |||
